edivir AB announced that the first patient has been enrolled and is being dosed with remetinostat gel 1% in an investigator-initiated phase II clinical study in patients with basal cell carcinoma (BCC).
STOCKHOLM, Aug. 2, 2018 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announced that the first patient has been enrolled and is being dosed with remetinostat gel 1% in an investigator-initiated phase II clinical study in patients with basal cell carcinoma (BCC). This clinical study will be conducted at the Stanford University School of Medicine in California, USA under the leadership of the principal investigator, Dr Kavita Sarin. Medivir will be providing remetinostat drug supply for this study, and will have full access to, and the rights to use, all clinical data after the study is complete.
The primary objective of the study is to assess the effects of topical remetinostat on the overall response rate in a cohort of BCC patients and could establish that remetinostat has the potential for use in other skin-associated cancers in addition to CTCL. Further details of the study can be found at www.clinicaltrials.gov with the reference NCT03180528.
“This study highlights the potential of remetinostat to be used in conditions beyond early-stage cutaneous T-cell lymphoma,” said Christine Lind, CEO of Medivir. She continues, “We look forward to the completion of the study and communication of the clinical outcomes.”
For further information, please contact:
Christine Lind, CEO, Medivir AB, phone: +46(0)8-5468-3100
Erik Björk, CFO, Medivir AB, mobile: +46(0)72-228-2831
About remetinostat
Remetinostat is a histone deacetylase (HDAC) inhibitor. The unique design of remetinostat enables topical application, making it active only in the skin. As soon as it reaches the blood stream, it is degraded, avoiding the side effects associated with other HDAC inhibitors.
About Medivir
Medivir is a research-based pharmaceutical company with a focus on oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical need. Medivir is listed on the Nasdaq Stockholm Mid Cap List (ticker: MVIR). www.medivir.com.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
http://mb.cision.com/Main/652/2585347/886176.pdf Press release (PDF)
View original content:http://www.prnewswire.com/news-releases/investigator-initiated-phase-ii-clinical-study-of-remetinostat-started-in-patients-with-basal-cell-carcinoma-300690987.html
SOURCE Medivir
Company Codes: Stockholm:MVIRB, Bloomberg:MVIRB@SS, ISIN:SE0000273294, RICS:MVIRB.ST
